Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Evinacumab-dgnb, sold by Regeneron under the brand name Evkeeza, can now be used to treat homozygous familial hypercholesterolemia in much younger patients.

AI-powered chatbots can be valuable resources when users have questions about cardiovascular health—but they are still far from perfect.

Cardiovascular disease remains the world’s leading cause of death, according to a special report from the American College of Cardiology. The new analysis, described by one cardiologist as a "wake-up call," includes data from more than 200 countries and territories.

Pediatric cardiologists can make a significant impact on global health trends by looking for early warning signs of CVD in their patients and collaborating with other physicians.

Researchers tracked real-world data from nearly 60,000 Medicare patients, highlighting the benefits of weekly injections of semaglutide. 

An oral version of the popular GLP-1 drug was associated with multiple benefits, including considerable improvements in BMI and waist circumference. Previous research found that it reduces certain heart risks in patients with type 2 diabetes.

The agency emphasized that many over-the-counter technologies marketed for this purpose have not been properly evaluated.